Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1, Open Label Trial to Evaluate the Safety and Immunogenicity of PAN-301-1 in Cancer Patients

Trial Profile

Phase 1, Open Label Trial to Evaluate the Safety and Immunogenicity of PAN-301-1 in Cancer Patients

Completed
Phase of Trial: Phase I

Latest Information Update: 11 Jan 2019

At a glance

  • Drugs SNS 301 (Primary)
  • Indications Prostate cancer
  • Focus Adverse reactions; First in man; Proof of concept
  • Sponsors Sensei Biotherapeutics
  • Most Recent Events

    • 06 Nov 2018 Results presented in the Sensei Biotherapeutics Media Release
    • 19 Oct 2018 Results published in the Sensei Biotherapeutics Media Release
    • 09 Oct 2018 Status changed from active, no longer recruiting to completed, according to a Sensei Biotherapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top